Synbiotics for prevention of ventilator-associated pneumonia: a probiotics strain-specific network meta-analysis.
- 2019-10-03
- The Journal of international medical research 47(11)
- PubMed: 31578896
- DOI: 10.1177/0300060519876753
Study Design
- Type
- Meta-Analysis
- Methods
- This systematic review and NMA was conducted according to the updated preferred reporting items for systematic review and meta-analysis. A systematic literature search of public databases from inception to 17 June 2018 was performed.
Abstract
Objective: Probiotics may be efficacious in preventing ventilator-associated pneumonia (VAP). The aim of this network meta-analysis (NMA) was to clarify the efficacy of different types of probiotics for preventing VAP.
Methods: This systematic review and NMA was conducted according to the updated preferred reporting items for systematic review and meta-analysis. A systematic literature search of public databases from inception to 17 June 2018 was performed.
Results: NMA showed that “Bifidobacterium longum + Lactobacillus bulgaricus + Streptococcus thermophiles” was more efficacious than “Ergyphilus” in preventing VAP (odds ratio: 0.15, 95% confidence interval: 0.03–0.94). According to pairwise meta-analysis, “B. longum + L. bulgaricus + S. thermophiles” and “Lactobacillus rhamnosus” were superior to placebo in preventing VAP. Treatment rank based on surface under the cumulative ranking curves revealed that the most efficacious treatment for preventing VAP was “B. longum + L. bulgaricus + S. thermophiles” (66%). In terms of reducing hospital mortality and ICU mortality, the most efficacious treatment was Synbiotic 2000FORTE (34% and 46%, respectively).
Conclusions: Based on efficacy ranking, “B. longum + L. bulgaricus + S. thermophiles” should be the first choice for prevention of VAP, while Synbiotic 2000FORTE has the potential to reduce in-hospital mortality and ICU mortality.
Keywords: Network meta-analysis; mortality; probiotics; randomized controlled trial; systematic review; ventilator-associated pneumonia.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|---|---|---|---|---|
| Lactobacillus bulgaricus SD-6833 | — | Reduced Hospital Mortality Rate | Beneficial | Small | View sourceIn terms of reducing hospital mortality and ICU mortality, the most efficacious treatment was Synbiotic 2000FORTE (34% and 46%, respectively). |
| Lactobacillus bulgaricus SD-6833 | — | Reduced Intensive Care Unit Mortality | Beneficial | Small | View sourceIn terms of reducing hospital mortality and ICU mortality, the most efficacious treatment was Synbiotic 2000FORTE (34% and 46%, respectively). |
| Lactobacillus bulgaricus SD-6833 | — | Reduced Ventilator-Associated Pneumonia | Beneficial | Moderate | View source"Bifidobacterium longum + Lactobacillus bulgaricus + Streptococcus thermophiles" was more efficacious than "Ergyphilus" in preventing VAP (odds ratio: 0.15, 95% confidence interval: 0.03–0.94). |